Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model
Identifieur interne : 000261 ( Istex/Corpus ); précédent : 000260; suivant : 000262Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model
Auteurs : Donato A. Di Monte ; Alison Mccormack ; Giselle Petzinger ; Ann Marie Janson ; Maryka Quik ; William J. LangstonSource :
- Movement Disorders [ 0885-3185 ] ; 2000-05.
English descriptors
- KwdEn :
Abstract
Presynaptic denervation is likely to play an important role in the pathophysiology of dyskinesias that develop after levodopa administration to patients with Parkinson's disease. In this study, the thresholds of nigrostriatal damage necessary for the occurrence of parkinsonism and levodopa‐induced involuntary movements were compared in squirrel monkeys lesioned with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). Animals treated with a regimen of MPTP that caused parkinsonism displayed ≥95% striatal dopamine depletion, 90% reduction of striatal dopamine uptake sites, and 70% nigral neuronal loss. Levodopa administration ameliorated the parkinsonian signs of these monkeys but also induced dyskinesias. A separate group of animals was treated with a milder MPTP regimen that caused 60%–70% striatal dopamine depletion, a 50% decrease in dopamine transporter, and 40% loss of dopaminergic nigral neurons. While these monkeys displayed no behavioral signs of parkinsonism, they all became dyskinetic after levodopa administration. The priming effect of levodopa, that is, the recurrence of dyskinesias in animals previously exposed to the drug, was compared in severely versus mildly lesioned monkeys. When severely injured parkinsonian animals underwent a second cycle of levodopa treatment, they immediately and consistently developed involuntary movements. In contrast, the recurrence of dyskinesias in primed monkeys with a partial nigrostriatal lesion required several levodopa administrations and remained relatively sporadic. The data indicate that moderate nigrostriatal damage which does not induce clinical parkinsonism predisposes to levodopa‐induced dyskinesias. Once dyskinesias have been induced, the severity of denervation may enhance the sensitivity to subsequent levodopa exposures.
Url:
DOI: 10.1002/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3
Links to Exploration step
ISTEX:D13248DD2462D4AB89728A6C73E0B4B654F8743ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model</title><author><name sortKey="Di Monte, Donato A" sort="Di Monte, Donato A" uniqKey="Di Monte D" first="Donato A." last="Di Monte">Donato A. Di Monte</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Mccormack, Alison" sort="Mccormack, Alison" uniqKey="Mccormack A" first="Alison" last="Mccormack">Alison Mccormack</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Petzinger, Giselle" sort="Petzinger, Giselle" uniqKey="Petzinger G" first="Giselle" last="Petzinger">Giselle Petzinger</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Janson, Ann Marie" sort="Janson, Ann Marie" uniqKey="Janson A" first="Ann Marie" last="Janson">Ann Marie Janson</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Langston, William J" sort="Langston, William J" uniqKey="Langston W" first="William J." last="Langston">William J. Langston</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D13248DD2462D4AB89728A6C73E0B4B654F8743A</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1002/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3</idno><idno type="url">https://api.istex.fr/document/D13248DD2462D4AB89728A6C73E0B4B654F8743A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000261</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model</title><author><name sortKey="Di Monte, Donato A" sort="Di Monte, Donato A" uniqKey="Di Monte D" first="Donato A." last="Di Monte">Donato A. Di Monte</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Mccormack, Alison" sort="Mccormack, Alison" uniqKey="Mccormack A" first="Alison" last="Mccormack">Alison Mccormack</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Petzinger, Giselle" sort="Petzinger, Giselle" uniqKey="Petzinger G" first="Giselle" last="Petzinger">Giselle Petzinger</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Janson, Ann Marie" sort="Janson, Ann Marie" uniqKey="Janson A" first="Ann Marie" last="Janson">Ann Marie Janson</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Langston, William J" sort="Langston, William J" uniqKey="Langston W" first="William J." last="Langston">William J. Langston</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2000-05">2000-05</date><biblScope unit="vol">15</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="459">459</biblScope><biblScope unit="page" to="466">466</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D13248DD2462D4AB89728A6C73E0B4B654F8743A</idno><idno type="DOI">10.1002/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3</idno><idno type="ArticleID">MDS1006</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine</term><term>Dyskinesias</term><term>Levodopa</term><term>MPTP</term><term>Monkeys</term><term>Parkinson's disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Presynaptic denervation is likely to play an important role in the pathophysiology of dyskinesias that develop after levodopa administration to patients with Parkinson's disease. In this study, the thresholds of nigrostriatal damage necessary for the occurrence of parkinsonism and levodopa‐induced involuntary movements were compared in squirrel monkeys lesioned with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). Animals treated with a regimen of MPTP that caused parkinsonism displayed ≥95% striatal dopamine depletion, 90% reduction of striatal dopamine uptake sites, and 70% nigral neuronal loss. Levodopa administration ameliorated the parkinsonian signs of these monkeys but also induced dyskinesias. A separate group of animals was treated with a milder MPTP regimen that caused 60%–70% striatal dopamine depletion, a 50% decrease in dopamine transporter, and 40% loss of dopaminergic nigral neurons. While these monkeys displayed no behavioral signs of parkinsonism, they all became dyskinetic after levodopa administration. The priming effect of levodopa, that is, the recurrence of dyskinesias in animals previously exposed to the drug, was compared in severely versus mildly lesioned monkeys. When severely injured parkinsonian animals underwent a second cycle of levodopa treatment, they immediately and consistently developed involuntary movements. In contrast, the recurrence of dyskinesias in primed monkeys with a partial nigrostriatal lesion required several levodopa administrations and remained relatively sporadic. The data indicate that moderate nigrostriatal damage which does not induce clinical parkinsonism predisposes to levodopa‐induced dyskinesias. Once dyskinesias have been induced, the severity of denervation may enhance the sensitivity to subsequent levodopa exposures.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Donato A. Di Monte MD</name><affiliations><json:string>The Parkinson's Institute, Sunnyvale, California, USA</json:string></affiliations></json:item><json:item><name>Alison McCormack</name><affiliations><json:string>The Parkinson's Institute, Sunnyvale, California, USA</json:string><json:string>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</json:string></affiliations></json:item><json:item><name>Giselle Petzinger MD</name><affiliations><json:string>The Parkinson's Institute, Sunnyvale, California, USA</json:string></affiliations></json:item><json:item><name>Ann Marie Janson MD, PhD</name><affiliations><json:string>The Parkinson's Institute, Sunnyvale, California, USA</json:string><json:string>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</json:string></affiliations></json:item><json:item><name>Maryka Quik PhD</name><affiliations><json:string>The Parkinson's Institute, Sunnyvale, California, USA</json:string></affiliations></json:item><json:item><name>William J. Langston MD</name><affiliations><json:string>The Parkinson's Institute, Sunnyvale, California, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Dyskinesias</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Dopamine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MPTP</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Monkeys</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Presynaptic denervation is likely to play an important role in the pathophysiology of dyskinesias that develop after levodopa administration to patients with Parkinson's disease. In this study, the thresholds of nigrostriatal damage necessary for the occurrence of parkinsonism and levodopa‐induced involuntary movements were compared in squirrel monkeys lesioned with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). Animals treated with a regimen of MPTP that caused parkinsonism displayed ≥95% striatal dopamine depletion, 90% reduction of striatal dopamine uptake sites, and 70% nigral neuronal loss. Levodopa administration ameliorated the parkinsonian signs of these monkeys but also induced dyskinesias. A separate group of animals was treated with a milder MPTP regimen that caused 60%–70% striatal dopamine depletion, a 50% decrease in dopamine transporter, and 40% loss of dopaminergic nigral neurons. While these monkeys displayed no behavioral signs of parkinsonism, they all became dyskinetic after levodopa administration. The priming effect of levodopa, that is, the recurrence of dyskinesias in animals previously exposed to the drug, was compared in severely versus mildly lesioned monkeys. When severely injured parkinsonian animals underwent a second cycle of levodopa treatment, they immediately and consistently developed involuntary movements. In contrast, the recurrence of dyskinesias in primed monkeys with a partial nigrostriatal lesion required several levodopa administrations and remained relatively sporadic. The data indicate that moderate nigrostriatal damage which does not induce clinical parkinsonism predisposes to levodopa‐induced dyskinesias. Once dyskinesias have been induced, the severity of denervation may enhance the sensitivity to subsequent levodopa exposures.</abstract><qualityIndicators><score>7.868</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1810</abstractCharCount><pdfWordCount>5220</pdfWordCount><pdfCharCount>33779</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>239</abstractWordCount></qualityIndicators><title>Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model</title><genre><json:string>Serial article</json:string></genre><host><volume>15</volume><pages><total>8</total><last>466</last><first>459</first></pages><issn><json:string>0885-3185</json:string></issn><issue>3</issue><subject><json:item><value>Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2000</publicationDate><copyrightDate>2000</copyrightDate><doi><json:string>10.1002/1531-8257(200005)15:3>459::AID-MDS1006>3.0.CO;2-3</json:string></doi><id>D13248DD2462D4AB89728A6C73E0B4B654F8743A</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/D13248DD2462D4AB89728A6C73E0B4B654F8743A/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/D13248DD2462D4AB89728A6C73E0B4B654F8743A/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/D13248DD2462D4AB89728A6C73E0B4B654F8743A/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><availability><p>John Wiley & Sons, Inc.</p></availability><date>2000</date></publicationStmt><notesStmt><note>NINDS - No. NS34886‐01A2;</note><note>Retirement Research Foundation</note><note>Lookout Fund Foundation</note><note>Mylan Pharmaceuticals</note><note>Swedish Medical Research Council - No. 10816;</note><note>Karolinska Institute Foundation</note><note>Kapten Arthur Eriksson, King Gustaf V and Queen Victoria Foundation</note><note>Fredrik and Ingrid Thuring Foundation</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model</title><author><persName><forename type="first">Donato A.</forename><surname>Di Monte</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: The Parkinson's Institute, 1170 Morse Avenue, Sunnyvale, CA 94089‐1605, U.S.A.</p></note><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation></author><author><persName><forename type="first">Alison</forename><surname>McCormack</surname></persName><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation><affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</affiliation></author><author><persName><forename type="first">Giselle</forename><surname>Petzinger</surname><roleName type="degree">MD</roleName></persName><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation></author><author><persName><forename type="first">Ann Marie</forename><surname>Janson</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation><affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</affiliation></author><author><persName><forename type="first">Maryka</forename><surname>Quik</surname><roleName type="degree">PhD</roleName></persName><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation></author><author><persName><forename type="first">William J.</forename><surname>Langston</surname><roleName type="degree">MD</roleName></persName><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2000-05"></date><biblScope unit="vol">15</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="459">459</biblScope><biblScope unit="page" to="466">466</biblScope></imprint></monogr><idno type="istex">D13248DD2462D4AB89728A6C73E0B4B654F8743A</idno><idno type="DOI">10.1002/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3</idno><idno type="ArticleID">MDS1006</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2000</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Presynaptic denervation is likely to play an important role in the pathophysiology of dyskinesias that develop after levodopa administration to patients with Parkinson's disease. In this study, the thresholds of nigrostriatal damage necessary for the occurrence of parkinsonism and levodopa‐induced involuntary movements were compared in squirrel monkeys lesioned with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). Animals treated with a regimen of MPTP that caused parkinsonism displayed ≥95% striatal dopamine depletion, 90% reduction of striatal dopamine uptake sites, and 70% nigral neuronal loss. Levodopa administration ameliorated the parkinsonian signs of these monkeys but also induced dyskinesias. A separate group of animals was treated with a milder MPTP regimen that caused 60%–70% striatal dopamine depletion, a 50% decrease in dopamine transporter, and 40% loss of dopaminergic nigral neurons. While these monkeys displayed no behavioral signs of parkinsonism, they all became dyskinetic after levodopa administration. The priming effect of levodopa, that is, the recurrence of dyskinesias in animals previously exposed to the drug, was compared in severely versus mildly lesioned monkeys. When severely injured parkinsonian animals underwent a second cycle of levodopa treatment, they immediately and consistently developed involuntary movements. In contrast, the recurrence of dyskinesias in primed monkeys with a partial nigrostriatal lesion required several levodopa administrations and remained relatively sporadic. The data indicate that moderate nigrostriatal damage which does not induce clinical parkinsonism predisposes to levodopa‐induced dyskinesias. Once dyskinesias have been induced, the severity of denervation may enhance the sensitivity to subsequent levodopa exposures.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>Dyskinesias</term></item><item><term>Levodopa</term></item><item><term>Dopamine</term></item><item><term>MPTP</term></item><item><term>Monkeys</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1999-12-20">Received</change><change when="2000-02-09">Registration</change><change when="2000-05">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/D13248DD2462D4AB89728A6C73E0B4B654F8743A/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/1531-8257(200005)15:3<>1.0.CO;2-5</doi><numberingGroup><numbering type="journalVolume" number="15">15</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="2000-05">May 2000</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="6" status="forIssue"><doi origin="wiley" registered="yes">10.1002/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3</doi><idGroup><id type="unit" value="MDS1006"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2000 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="1999-12-20"></event><event type="manuscriptRevised" date="2000-02-09"></event><event type="manuscriptAccepted" date="2000-02-09"></event><event type="firstOnline" date="2001-01-31"></event><event type="publishedOnlineFinalForm" date="2001-01-31"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">459</numbering><numbering type="pageLast">466</numbering></numberingGroup><correspondenceTo>The Parkinson's Institute, 1170 Morse Avenue, Sunnyvale, CA 94089‐1605, U.S.A.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS1006.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="4"></count><count type="referenceTotal" number="35"></count><count type="wordTotal" number="5051"></count></countGroup><titleGroup><title type="main" xml:lang="en">Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model</title><title type="short" xml:lang="en">Nigrostriatal Denervation and Dyskinesias</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Donato A.</givenNames><familyName>Di Monte</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Alison</givenNames><familyName>McCormack</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Giselle</givenNames><familyName>Petzinger</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Ann Marie</givenNames><familyName>Janson</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Maryka</givenNames><familyName>Quik</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>William J.</givenNames><familyName>Langston</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>The Parkinson's Institute, Sunnyvale, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="SE" type="organization"><unparsedAffiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">Dyskinesias</keyword><keyword xml:id="kwd3">Levodopa</keyword><keyword xml:id="kwd4">Dopamine</keyword><keyword xml:id="kwd5">MPTP</keyword><keyword xml:id="kwd6">Monkeys</keyword></keywordGroup><fundingInfo><fundingAgency>NINDS</fundingAgency><fundingNumber>NS34886‐01A2</fundingNumber></fundingInfo><fundingInfo><fundingAgency>Retirement Research Foundation</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Lookout Fund Foundation</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Mylan Pharmaceuticals</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Swedish Medical Research Council</fundingAgency><fundingNumber>10816</fundingNumber></fundingInfo><fundingInfo><fundingAgency>Karolinska Institute Foundation</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Kapten Arthur Eriksson, King Gustaf V and Queen Victoria Foundation</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Fredrik and Ingrid Thuring Foundation</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Presynaptic denervation is likely to play an important role in the pathophysiology of dyskinesias that develop after levodopa administration to patients with Parkinson's disease. In this study, the thresholds of nigrostriatal damage necessary for the occurrence of parkinsonism and levodopa‐induced involuntary movements were compared in squirrel monkeys lesioned with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). Animals treated with a regimen of MPTP that caused parkinsonism displayed ≥95% striatal dopamine depletion, 90% reduction of striatal dopamine uptake sites, and 70% nigral neuronal loss. Levodopa administration ameliorated the parkinsonian signs of these monkeys but also induced dyskinesias. A separate group of animals was treated with a milder MPTP regimen that caused 60%–70% striatal dopamine depletion, a 50% decrease in dopamine transporter, and 40% loss of dopaminergic nigral neurons. While these monkeys displayed no behavioral signs of parkinsonism, they all became dyskinetic after levodopa administration. The priming effect of levodopa, that is, the recurrence of dyskinesias in animals previously exposed to the drug, was compared in severely versus mildly lesioned monkeys. When severely injured parkinsonian animals underwent a second cycle of levodopa treatment, they immediately and consistently developed involuntary movements. In contrast, the recurrence of dyskinesias in primed monkeys with a partial nigrostriatal lesion required several levodopa administrations and remained relatively sporadic. The data indicate that moderate nigrostriatal damage which does not induce clinical parkinsonism predisposes to levodopa‐induced dyskinesias. Once dyskinesias have been induced, the severity of denervation may enhance the sensitivity to subsequent levodopa exposures.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Nigrostriatal Denervation and Dyskinesias</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model</title></titleInfo><name type="personal"><namePart type="given">Donato A.</namePart><namePart type="family">Di Monte</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation><description>Correspondence: The Parkinson's Institute, 1170 Morse Avenue, Sunnyvale, CA 94089‐1605, U.S.A.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alison</namePart><namePart type="family">McCormack</namePart><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation><affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Giselle</namePart><namePart type="family">Petzinger</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ann Marie</namePart><namePart type="family">Janson</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation><affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Maryka</namePart><namePart type="family">Quik</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">William J.</namePart><namePart type="family">Langston</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>John Wiley & Sons, Inc.</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2000-05</dateIssued><dateCaptured encoding="w3cdtf">1999-12-20</dateCaptured><dateValid encoding="w3cdtf">2000-02-09</dateValid><copyrightDate encoding="w3cdtf">2000</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">4</extent><extent unit="references">35</extent><extent unit="words">5051</extent></physicalDescription><abstract lang="en">Presynaptic denervation is likely to play an important role in the pathophysiology of dyskinesias that develop after levodopa administration to patients with Parkinson's disease. In this study, the thresholds of nigrostriatal damage necessary for the occurrence of parkinsonism and levodopa‐induced involuntary movements were compared in squirrel monkeys lesioned with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). Animals treated with a regimen of MPTP that caused parkinsonism displayed ≥95% striatal dopamine depletion, 90% reduction of striatal dopamine uptake sites, and 70% nigral neuronal loss. Levodopa administration ameliorated the parkinsonian signs of these monkeys but also induced dyskinesias. A separate group of animals was treated with a milder MPTP regimen that caused 60%–70% striatal dopamine depletion, a 50% decrease in dopamine transporter, and 40% loss of dopaminergic nigral neurons. While these monkeys displayed no behavioral signs of parkinsonism, they all became dyskinetic after levodopa administration. The priming effect of levodopa, that is, the recurrence of dyskinesias in animals previously exposed to the drug, was compared in severely versus mildly lesioned monkeys. When severely injured parkinsonian animals underwent a second cycle of levodopa treatment, they immediately and consistently developed involuntary movements. In contrast, the recurrence of dyskinesias in primed monkeys with a partial nigrostriatal lesion required several levodopa administrations and remained relatively sporadic. The data indicate that moderate nigrostriatal damage which does not induce clinical parkinsonism predisposes to levodopa‐induced dyskinesias. Once dyskinesias have been induced, the severity of denervation may enhance the sensitivity to subsequent levodopa exposures.</abstract><note type="funding">NINDS - No. NS34886‐01A2; </note><note type="funding">Retirement Research Foundation</note><note type="funding">Lookout Fund Foundation</note><note type="funding">Mylan Pharmaceuticals</note><note type="funding">Swedish Medical Research Council - No. 10816; </note><note type="funding">Karolinska Institute Foundation</note><note type="funding">Kapten Arthur Eriksson, King Gustaf V and Queen Victoria Foundation</note><note type="funding">Fredrik and Ingrid Thuring Foundation</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>Dyskinesias</topic><topic>Levodopa</topic><topic>Dopamine</topic><topic>MPTP</topic><topic>Monkeys</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>459</start><end>466</end><total>8</total></extent></part></relatedItem><identifier type="istex">D13248DD2462D4AB89728A6C73E0B4B654F8743A</identifier><identifier type="DOI">10.1002/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3</identifier><identifier type="ArticleID">MDS1006</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2000 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>John Wiley & Sons, Inc.</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000261 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000261 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:D13248DD2462D4AB89728A6C73E0B4B654F8743A
|texte= Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model
}}
| This area was generated with Dilib version V0.6.23. |  |